SCHEMBL383452

SCHEMBL383452

CC(c1ccccc1)[C@H](N)C(=O)O

nearest known ligand 0.55

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.51
ALOX5 P09917 1/20 0.50
LMNA P02545 3/20 0.48
ADRA2A P08913 1/20 0.48
ADRA2C P18825 1/20 0.48
HIF1A Q16665 1/20 0.48
KDM4E B2RXH2 1/20 0.48
CYP2D6 P10635 1/20 0.48
SRC P12931 1/20 0.48
ALDH1A1 P00352 1/20 0.47
MAPK1 P28482 1/20 0.46
SLC7A5 Q01650 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL180086 1.00 DPP4 (0.51) DPP4ALOX5LMNAADRA2AADRA2C
SCHEMBL5687563 1.00 DPP4 (0.51) DPP4ALOX5LMNAADRA2AADRA2C
SCHEMBL5687646 1.00 DPP4 (0.51) DPP4ALOX5LMNAADRA2AADRA2C
SCHEMBL30360242 1.00 DPP4 (0.51) DPP4ALOX5LMNAADRA2AADRA2C
SCHEMBL383451 1.00 DPP4 (0.51) DPP4ALOX5LMNAADRA2AADRA2C
SCHEMBL24156377 1.00 DPP4 (0.51) DPP4ALOX5LMNAADRA2AADRA2C
SCHEMBL8882516 1.00 DPP4 (0.51) DPP4ALOX5LMNAADRA2AADRA2C
Hydrochloric Acid SCHEMBL2317097 0.98 DPP4 (0.50) DPP4ALOX5LMNAADRA2AADRA2C
Hydrochloric Acid SCHEMBL2317093 0.98 DPP4 (0.50) DPP4ALOX5LMNAADRA2AADRA2C
Hydrochloric Acid SCHEMBL30486422 0.98 DPP4 (0.50) DPP4ALOX5LMNAADRA2AADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 549 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122028793-A Fungicidal compositions 先正达农作物保护股份公司 2026-05-12 CN claimed
US-20250296959-A1 B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF MARIANA ONCOLOGY INC (US) 2025-09-25 US claimed
WO-2024215515-A1 DRUG LINKERS AND ANTIBODY CONJUGATES THEREOF AMBRX, INC. (US) 2024-10-17 WO claimed
CN-114457049-B Pyrrolysiyl-tRNA synthetase mutant and application thereof 浙江大学杭州国际科创中心 2024-09-24 CN claimed
WO-2024178310-A1 TROP2-DIRECTED ANTIBODY-DRUG CONJUGATES AND USES THEREOF AMBRX, INC. (US) 2024-08-29 WO claimed
WO-2024178360-A2 AURISTATIN ANALOGS AND ANTIBODY CONJUGATES THEREOF AMBRX, INC. (US) 2024-08-29 WO claimed
US-20230303647-A1 CYCLIC CHEMERIN-9 DERIVATIVES BAYER AKTIENGESELLSCHAFT (DE) 2023-09-28 US claimed
CN-116390742-A Cyclic chemokine-9 derivatives 拜耳公司 2023-07-04 CN claimed
EP-4196143-A1 CYCLIC CHEMERIN-9 DERIVATIVES Bayer Aktiengesellschaft (DE) 2023-06-21 EP claimed
US-20230111252-A1 THIOSEMICARBAZATES AND USES THEREOF THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2023-04-13 US claimed
EP-1046627-B1 Enantiopure reagents and process for the separation of enantiomers SOLVAY (BE) 2004-02-11 EP claimed
EP-1046627-A2 Enantiopure reagents and process for the separation of enantiomers SOLVAY (Société Anonyme) (BE) 2000-10-25 EP claimed
CN-1036832-C Composition containing a penem or carbapenem artibiotic and the use of the same SANKYO CO (JP) 1997-12-31 CN claimed
EP-0352092-B1 Novel antibiotics R106 TAKARA SHUZO CO (JP) 1993-10-27 EP claimed
EP-0226304-B1 COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC SANKYO COMPANY LIMITED (JP) 1991-08-28 EP claimed
EP-0352092-A2 Novel antibiotics R106 TAKARA SHUZO CO. LTD. (JP) 1990-01-24 EP claimed
US-4757066-A Reduces renal toxicity SANKYO COMPANY LIMITED (JP) 1988-07-12 US claimed
EP-0226304-A1 Composition containing a penem or carbapenem antibiotic SANKYO COMPANY LIMITED (JP) 1987-06-24 EP claimed
US-4668796-A Racemates of optically active bicyclic imino-alpha-carboxylic esters HOECHST AKTIENGESELLSCHAFT (DE) 1987-05-26 US claimed
CN-86107574-A Compositions containing penem or carbapenem antibiotics and their use 1987-05-20 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250296959-A1 B7-H3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF CD274, CD44, CD74 DPP4 2866/4885ALOX5 4551/4885LMNA 3408/4885
US-20230111252-A1 THIOSEMICARBAZATES AND USES THEREOF TST, ABAT, AADAC DPP4 63/4885ALOX5 2603/4885LMNA 4387/4885
US-20230303647-A1 CYCLIC CHEMERIN-9 DERIVATIVES CMKLR1, CMKLR2, CCL2 DPP4 671/4885ALOX5 1574/4885LMNA 2262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.